Biological, genetic, and clinical data provide compelling proof for N-type voltage-gated calcium channels (CaV2.2) as therapeutic targets for chronic pain. While decreasing channel function is ultimately anti-nociceptive, directly targeting the channel can lead to multiple adverse effects. Targeting regulators of channel activity may facilitate improved analgesic properties associated with channel block and afford a broader therapeutic window. Towards this end, we recently identified a short peptide, designated CBD3, derived from collapsin response mediator protein 2 (CRMP-2) that suppressed inflammatory and neuropathic hypersensitivity by inhibiting CRMP-2 binding to CaV2.2 [Brittain et al., Nature Medicine 17:822-829 (2011)]. Rodents administered CBD3 intraperitoneally, fused to the HIV TAT protein cell penetrating domain, exhibited antinociception lasting ~4 hours highlighting potential instability, limited oral bioavailability, and/or rapid elimination of peptide. This report focuses on improving upon the parental CBD3 peptide. Using SPOTScan analysis of synthetic versions of the parental CBD3 peptide, we identified peptides harboring single amino acid mutations that bound with greater affinity to CaV2.2. One such peptide, harboring a phenylalanine instead of glycine (G14F), was tested in rodent models of migraine and neuropathic pain. In vivo laser Doppler blood flowmetry measure of capsaicin-induced meningeal vascular responses related to headache pain was almost completely suppressed by dural application of the G14F peptide. The G14F mutant peptide, administered intraperitoneally, also exhibited greater antinociception in Stavudine (2'-3'-didehydro-2'-3'-dideoxythymidine (d4T)/Zerit®) model of AIDS therapy-induced peripheral neuropathy compared to the parent CBD3 peptide. These results demonstrate the patent translational value of small biologic drugs targeting CaV2.2 for management of clinical pain.
introduction
The management of severe chronic pain in patients is challenging as often the reason for the pain is not clear and effective pharmacological treatment is difficult to achieve with currently available drugs [1] . One recent success story for chronic neuropathic pain treatment is the FDA approval of a synthetic w-conotoxin, Ziconotide (Prialt ®), which serves to block a voltage-gated ion channel, known as the N-type voltage-gated calcium channel, (CaV2.2) [2] . By this mechanism, Ziconotide effectively reduces pain. However, ziconotide can only be used to treat a small subset of patients, has a narrow therapeutic window due to the numerous offtarget effects within and external to the CNS. N-type calcium channels are multiprotein complexes comprised of a pore-forming α-subunits and auxiliary α2/δ, β, and g subunits [3] . CaV2.2 channels serve as the nidus for pain transduction as mice lacking CaV2.2 exhibit an increased threshold for pain [4] , and expression of CaV2.2 is upregulated following a chronic constrictive nerve injury [5] . The importance of CaV2.2 in pain is further highlighted by the demonstration of a naturally occurring alternative splice form of CaV2.2 (i.e., exon 37a) in small-diameter nociceptors [6] ; neurons with exon 37a containing CaV2.2 are critical for thermal hyperalgesia, and thermal and mechanical nociception [7] . Mechanistically, the presence of CaV2.2 in the presynaptic nerve terminal of primary afferent nociceptive neurons is thought to release excitatory neurotransmitters into the synapse present between nociceptive neurons of the peripheral nervous system and the dorsal horn of the spinal cord. In sum, by virtue of their ability to control the regulated release of neurotransmitters, the N-type Ca 2+ channels are a prime target for the development of novel analgesics [2, 8, 9] .
The purported pharmacological mechanism 
Drug administration
Drugs or peptides were diluted fresh daily in SIF.
TAT-CBD3 G14F was administered to the dural surface (50 µl, 10 µM). Capsaicin was dissolved in SIF to 100 nM for nasal administration. To stimulate the nasal mucosa, 50 µl of capsaicin solution was applied over a 30 s period at a site 2 mm into the right nostril using a Pipetman pipette [24] . SIF or SIF containing 0.1% ethanol was applied to the dura or nasal mucosa as a control in all experiments 15 minutes prior to drug application and had no effect on meningeal blood flow. 3 through the last day of testing at PID42 [25] .
Data collection and statistics
The von Frey test was performed on the area of the hind paws as previously described [21, 26] . Briefly, the rat was placed animals that did not respond at 120 mN were assigned that value.
Measurements were taken on 3 successive days before rats were subjected to peptides.
At least 6 rats were used per condition. Stimuli Further, the region of the CBD3 is likely surface exposed and thus available for protein-protein interactions ( Figure 1C ).
Results

CBD3
G14F blunts meningeal blood flow in an animal model of migraine
The dura mater is innervated by trigeminal capsaicin-sensitive peptidergic nociceptive prior to capsaicin significantly inhibited the capsaicin-induced blood flow changes [21] .
Here, we tested if G14F variant of CBD3 was similarly effective. Changes in meningeal blood flow in response to 100 nM capsaicin were assayed using laser Doppler flowmetry as previously described [21, 22, 31] . The peptide was administered topically to the dura 15 min before nasal administration of capsaicin.
G14F significantly reduced capsaicin evoked changes in blood flow (Cap, 35 ± 5% (n = 9) versus G14F, 7 ± 5% (n = 6); Figure 2B ). Basal blood flow was not altered by the peptide compared to saline (Sal, -1 ± 2% (n = 9) versus G14F, -3 ± 2% (n = 6)). There was no effect of G14F administration alone on basal blood for AIDS includes drugs such as zidovudine (AZT), zalcitabine (ddC), didanosine (ddI) and stavudine (d4T) that produce side-effects including painful neuropathies. The ability of peptides to reverse tactile hypersensitivity was evaluated in rats seven days after a single injection of d4T. TAT-CBD3 alone had no effect on paw withdrawal threshold (PWT) (Figure 4) . TAT-CBD3, but not TAT-reverse, caused an increase in PWT when administered intraperitoneally (i.p.) (Figure 4 ). In contrast, at the same i.p. dose of 10 mg/kg, TAT-CBD3-G14F produced a complete reversal of tactile hypersensitivity at 1 h after i.p. injection. Four hours after injection, TAT-CBD3 was no longer effective whereas TAT-CBD3-G14F-induced reversal of hypersensitivity had diminished by 50% but was still significantly better than control. By 24 hours, the effect of both peptides had subsided with no difference in hypersensitivity compared to d4T-treated rats (Figure 4 ).
discussion
In this report, we demonstrate that a variant of Calcium influx through these channels is the primary mechanism underlying substance P and CGRP release from these fibers [2, 9, 35] .
Pharmacologic block of CaV2.2 not only reduces neurotransmitter release but may also decrease the excitability of the postsynaptic neurons within lamina I of the spinal cord [35] . We had previously shown that CRMP-2 modulates CGRP release from dorsal root ganglia [14] . Therefore, we tested the novel CBD3 variant in a model of meningeal vasodilatation in response to noxious stimuli [21] . In this model of 'migraine' , activation [44] , resulting in discontinuation of use in up to 10% of the patients. This model of chronic pain employs the anti-retroviral treatment 2'-3'-didehydro-2'-3'-dideoxythymidine (d4T) to induce the small fiber dying back neuropathy that is seen in post-treatment AIDS patients [25] .
Animals treated with d4T exhibit hyperalgesia and allodynia [25] . The effect of the novel G14F 
